|[November 27, 2012]
Dendreon Announces Webcast Presentations at Upcoming Conferences
SEATTLE --(Business Wire)--
November 27, 2012--Dendreon Corporation (Nasdaq:DNDN) today
announced that management will present at the following conferences:
2012 dbAccess BioFEST in Boston, MA, on December 4, 2012, at 2:15 p.m.
31st Annual J.P. Morgan Healthcare Conference in San
Francisco, CA (News - Alert), on January 7, 2013, at 3:30 p.m. PT
The presentations will be webcast live and available for replay from
Dendreon's website, www.dendreon.com.
If you ae unable to listen to the live webcast, it will be archived on
the site following the presentation. To access the replay, go to the
Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to
target cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company
applies its expertise in antigen identification, engineering and cell
processing to produce active cellular immunotherapy (ACI) product
candidates designed to stimulate an immune response in a variety of
tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was
approved by the U.S. Food and Drug Administration (FDA) in April 2010.
Dendreon is exploring the application of additional ACI product
candidates and small molecules for the potential treatment of a variety
of cancers. The Company is headquartered in Seattle, Washington and is
traded on the NASDAQ Global Market under the symbol DNDN. For more
information about the Company and its programs, visit http://www.dendreon.com/.
[ Back To TMCnet.com's Homepage ]